Please assess the completion status of the following clinical trial:

Trial Title: Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Self-identified Black, African or African American women of ≥ 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)~2. ER-positive and/or PgR-positive tumor based on local laboratory results~3. HER2-negative breast cancer based on local laboratory results (test to be used as per local practice)~4. Patients must be appropriate candidates for letrozole or fulvestrant therapy~5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2~6. Adequate bone marrow function:~   * Absolute Neutrophil Count (ANC) ≥ 1,000/mm3 (1.0 x 109/L);~  * Platelets ≥100,000/mm3 (100 x 109/L);~  * Hemoglobin ≥9 g/dL (90 g/L).~Exclusion Criteria:~1. Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4~2. Active uncontrolled or symptomatic brain metastases. Previously treated and clinically stable, as per Investigator's judgment, brain metastases are permitted.~3. Previous CDK4/6 inhibitor~   -

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palbociclib + Letrozole or Fulvestrant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).